A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems

This study is open to healthy people and people with liver problems. Adults between 18 and 80 years can participate. The purpose of this study is to compare how a medicine called BI 3000202 is handled by the body in people with and without liver problems. All participants take 1 tablet of BI 3000202. Participants with liver problems may also continue their regular treatment for their liver condition. Participants are in the study for about 1 month. During this time, participants visit the study site about 11 times. Where possible, some of these visits may happen by phone. For some visits, participants stay at the study site overnight. Doctors regularly test the amount of BI 3000202 in the blood and check for any health problems.

NCT Number	NCT07486102
Lead Sponsor	Boehringer Ingelheim
Conditions	Healthy, Hepatic Impairment
Enrollment	44 participants
Start Date	2026-05-01
Primary Completion	2027-02-26 (estimated)
Study Completion	2027-02-27 (estimated)
Updated on ClinicalTrials.gov	2026-05-14